Submitted Successfully!
To reward your contribution, here is a gift for you: A free trial for our video production service.
Thank you for your contribution! You can also upload a video entry or images related to this topic.
Version Summary Created by Modification Content Size Created at Operation
1 -- 2526 2022-07-27 13:03:10 |
2 format corrected. + 57 word(s) 2583 2022-07-28 03:31:20 |

Video Upload Options

Do you have a full video?

Confirm

Are you sure to Delete?
Cite
If you have any further questions, please contact Encyclopedia Editorial Office.
Gkesoglou, T.;  Bargiota, S.I.;  Iordanidou, E.;  Vasiliadis, M.;  Bozikas, V.;  Agorastos, A. Peripheral Prognostic Biomarkers in Treatment-Resistant Depression. Encyclopedia. Available online: https://encyclopedia.pub/entry/25582 (accessed on 19 April 2024).
Gkesoglou T,  Bargiota SI,  Iordanidou E,  Vasiliadis M,  Bozikas V,  Agorastos A. Peripheral Prognostic Biomarkers in Treatment-Resistant Depression. Encyclopedia. Available at: https://encyclopedia.pub/entry/25582. Accessed April 19, 2024.
Gkesoglou, Theano, Stavroula I. Bargiota, Eleni Iordanidou, Miltiadis Vasiliadis, Vasilios-Panteleimon Bozikas, Agorastos Agorastos. "Peripheral Prognostic Biomarkers in Treatment-Resistant Depression" Encyclopedia, https://encyclopedia.pub/entry/25582 (accessed April 19, 2024).
Gkesoglou, T.,  Bargiota, S.I.,  Iordanidou, E.,  Vasiliadis, M.,  Bozikas, V., & Agorastos, A. (2022, July 27). Peripheral Prognostic Biomarkers in Treatment-Resistant Depression. In Encyclopedia. https://encyclopedia.pub/entry/25582
Gkesoglou, Theano, et al. "Peripheral Prognostic Biomarkers in Treatment-Resistant Depression." Encyclopedia. Web. 27 July, 2022.
Peripheral Prognostic Biomarkers in Treatment-Resistant Depression
Edit

Treatment-resistant depression (TRD) accounts for approximately 30–40% of patients with major depressive disorder (MDD) and is related to a large direct and indirect societal financial burden that represents up to 70% of MDD’s total cost. Partial- or non-responsiveness to antidepressive treatment contributes to disease chronicity, poor quality of life and lower productivity, leading to a significant increase in healthcare expenses, as well as higher relapse rates and suicide risk. Patients with TRD visit general practitioners seven times more often and have three times longer durations of hospitalizations than MDD patients. Impressively, the annual cost of TRD in the U.S.A. alone is estimated at 44 billion dollars. The discovery of new biomarkers and the better clinical characterization of known biomarkers could support the better classification and staging of TRD, the development of personalized treatment algorithms with higher rates of remission and fewer side effects, and the development of new precision drugs for specific subgroups of patients. 

major depressive disorder treatment-resistant depression antidepressants biomarkers treatment response

1. Immune and Inflammatory Biomarkers

The “immune hypothesis” of major depressive disorder (MDD) suggests a strong link between MDD and a dysfunctional immune system, while mounting research data indicate the significant role of several pro-inflammatory pathways in the pathophysiology of the disorder [1][2][3]. Accordingly, both immune and inflammatory biomarkers have been extensively studied with respect to their potential for predicting responses to antidepressant treatment. For example, several meta-analyses have repeatedly indicated that levels of tumor necrosis factor-alpha (TNF-α), interleukin-6 (IL-6), IL-1β, brain-derived neurotrophic factor (BDNF), IL-8 and c-reactive-protein (CRP) in peripheral blood serum are reliable biomarkers of antidepressant treatment response in MDD [4][5]. More specifically, higher baseline levels of TNF-α, IL-6, BDNF, IL-1β, and CRP, as well as lower IL-8 levels in the blood, are related to poorer responses to pharmacotherapy in MDD. However, there are also studies that do not confirm these results [4][5][6][7][8][9][10], while especially in TRD, respective research addressing baseline immune and inflammatory biomarkers for the prediction of treatment response is relatively scarce.

1.1. IL-1β

The researchers have identified three studies regarding the assessment of treatment response prediction in TRD with respect to IL-1β baseline levels. In an open study of ketamine infusion as monotherapy, in a sample of 16 TRD patients, Yang et al. reported significantly higher IL-1β serum baseline levels, as well as significantly reduced IL-1β levels 230 min and 1 day after ketamine infusion in responders compared to non-responders [11]. In contrast, in a similar study of 33 TRD patients, Kiraly et al. did not find any correlation between IL-1β baseline levels and treatment response to i.v. ketamine as monotherapy [12]. Similarly, an open study of add-on electroconvulsive therapy (ECT) in a sample of 29 patients with TRD by Kruse et al., also showed no correlation between IL-1β baseline blood levels and response to treatment [13], suggesting that IL-1β baseline levels have no prognostic value for treatment response in TRD.

1.2. IL-6

With respect to IL-6, there is a better line of evidence concerning its predictive value, as several studies have reported an association between plasma IL-6 and treatment response in TRD, while a recent systematic review by Yang et al. concluded that higher baseline levels of IL-6 predicted better responses in patients with TRD, although several contradictory results were reported [14]. In particular, a study by Chen et al. assessed the add-on use of intravenous ketamine in TRD patients and pointed out a connection between higher baseline levels of IL-6 and a better response to therapy in the group subjected to 0.5 mg/kg ketamine infusion but different results in the groups receiving 0.2 mg/kg ketamine and a placebo [15]. Similarly, Yang et al. also noted significantly higher baseline levels of IL-6 in TRD responders to 0.5 mg/kg ketamine infusion monotherapy compared to the group of non-responders [11], while in the ECT add-on study by Kruse et al., higher levels of IL-6 prior to treatment also predicted lower scores in the Montgomery–Asberg Depression Rating Scale following a course of treatment in females, but not in men [13]. In addition, in an add-on study of metyrapone on SSRI treatment in 63 TRD patients, Strawbridge et al. indicated a correlation between higher baseline levels of IL-6 and poorer responses to treatment [16].
On the other hand, Kiraly et al. didn’t discover any prognostic association between IL-6 levels and responses to treatment with 0.5 mg/kg ketamine infusion monotherapy in TRD patients [12]. Similarly, Kagawa et al. found no correlation between baseline IL-6 levels and clinical responses in augmentation therapy with lamotrigine in TRD patients, nor between baseline IL-6 levels and improvements in MADRS score [17]. Allen et al. also failed to find any association between baseline IL-6 levels and responses to treatment with 0.5 mg/kg ketamine infusion or ECT monotherapy in TRD patients, although a correlation between the greater decrease of depressive symptoms and higher baseline levels of IL-6 was found only in the first 24 hours post ketamine infusion [18]. Finally, Yoshimura et al. concluded that baseline levels of IL-6 in the blood had no prognostic value with respect to treatment response in patients resistant to therapy with SSRIs/SNRIs [19].

1.3. IL-8

With respect to the predictive significance of baseline IL-8 levels for treatment responses in TRD, the researchers could identify only three studies; of these, one study concluded that higher baseline levels of IL-8 were related to less serious depressive symptoms after the third infusion of 0.5 mg/kg ketamine in patients with TRD but not for other time points during treatment [18]. The two other studies could not report any prognostic correlation between baseline IL-8 levels and responses to treatment under 0.5 mg/kg ketamine infusion monotherapy [12] or ECT add-on treatment [13].

1.4. IL-10

Only three studies were found that investigated the prognostic value of baseline IL-10 levels on treatment responses in TRD patients. Allen et al. [18] and Kiraly et al. [12] both could not show any correlation between baseline IL-10 and responses to treatment with 0.5 mg/kg ketamine infusion monotherapy, while Strawbridge et al. also reported no prognostic value of baseline IL-10 on treatment responses in an add-on study of metyrapone on SSRI treatment in 63 TRD patients [16].

1.5. IFN-γ

The two studies by Allen et al. [18] and Kiraly et al. [12] were the only studies found to investigate an association between baseline INF-γ levels and treatment response to 0.5 mg/kg ketamine infusion monotherapy in TRD patients, and both failed to find any significant prognostic correlations, which is also supported by missing supportive data for INF-γ in the systematic review of Yang et al. [14].

1.6. TNF-α

Several studies have assessed the prognostic value of baseline TNF-a levels in blood and treatment responses in TRD; however, most of them failed to report any prognostic correlations. For example, Chen et al. found that baseline TNF-a levels were not associated with treatment outcomes for both 0.5 and 0.2 mg/kg i.v. doses of add-on ketamine treatment in 47 TRD patients [15]. Similarly, the two studies by Yang et al. [11] and Kiraly et al. [12] on the treatment response of TRD patients to 0.5 mg/kg ketamine infusion monotherapy did not find differences in baseline TNF-a levels between responders and non-responders to 0.5 mg/kg ketamine infusion monotherapy, and could not report any prognostic correlation between baseline TNF-a and treatment response. In addition, no prognostic correlation between baseline TNF-a levels and treatment response was found in studies assessing the response to ECT add-on treatment [13], SSRI/SNRI add-on therapy [19], and metyrapone add-on treatment to SSRIs [16] in patients with TRD. The systematic review by Yang et al. also did not find any supporting data for the prognostic value of TNF-a in clinical response trials in TRD [14]. However, the experimental trial by Raison et al., assessing the treatment response of TRD patients with mild resistance to treatment with the functional TNF-a antagonist infliximab, was the only study that could show that higher baseline TNF-a levels were associated with a better treatment response [20].

1.7. CRP

A large number of studies have assessed the predictive value of baseline peripheral CRP levels within TRD treatment response, and the recent systematic review by Yang et al. actually supports a clinically significant prognostic association between higher CRP reference levels and a better treatment response [14]. For example, the study by Raison et al. found that baseline levels of hsCRP > 5mg/L predicted a larger decrease in Hamilton (HAMD)-17 scale scores in 30 TRD patients with mild resistance to treatment receiving infliximab treatment [20], while Papakostas et al. also reported a larger decrease of HAMD-17 scores in SSRI-resistant depressive patients with higher levels of hsCRP receiving adjunctive therapy with L-methylfolate [21]. However, some studies have shown conflicting or negative results. For example, no prognostic correlations between baseline peripheral CRP levels and treatment response were found in studies assessing the response of TRD patients to both 0.5 and 0.2 mg/kg i.v. doses of add-on ketamine [15] or metyrapone treatment [16]. Interestingly, in their ECT add-on study, Kruse et al. pointed out that baseline CRP levels correlated significantly with final MADRS scores at the end of treatment in the female TRD sample only, while no correlation could be found with respect to the changes in the MADRS score in the total sample of patients [13].

1.8. BDNF and Other Growth Factors

Growth factors, like brain-derived neurotrophic factor (BDNF) have been often investigated as response biomarkers of depression treatment and especially implicated in the rapid mechanism of action of ketamine [22][23]. In addition, BDNF is considered to play an important role in the neuroimmune and inflammatory pathophysiology of MDD [24][25]. However, to date, only a few studies have managed to show some correlation between BDNF and treatment response in TRD.
For example, the ECT add-on study of Piccini et al., in 18 patients with TRD, reported lower baseline BDNF levels in patients vs. the control subjects, an increase in BDNF after treatment and, most importantly, higher BDNF baseline levels in responders than in non-responders [26]. Similarly, Haile et al. investigated 22 patients with TRD and found that i.v. ketamine monotherapy resulted in a higher BDNF increase in the serum of the responders than in the non-responders, as well as a negative correlation between MADRS scores and BDNF levels [27]. However, there was no significant prognostic correlation between BDNF baseline levels and responses to treatment with ketamine [27]. On the other hand, a study of treatment responses to add-on riluzole or a placebo in 55 TRD patients by Wilkinson et al. reported lower baseline levels of BDNF in responders to riluzole or the placebo compared to non-responders, although the statistical significance remained within the trend level [28].
Nevertheless, most studies assessing baseline peripheral BDNF could not show any correlation with respect to treatment response. For instance, in an add-on ECT response study of 74 patients with TRD, Maffioletti et al. could not show any difference between the baseline BDNF levels in responders and in non-responders [29]. Similarly, Huang et al. also showed no correlation between the baseline levels of BDNF in serum and responses to treatment in a comparison study of ECT vs. anesthesia with ketamine and propophol in 30 TRD patients [30], as did Allen et al. in a monotherapy study with either ECT or 0.5 mg/kg i.v. ketamine infusion in a group of 35 patients with TRD [31]. Likewise, Kagawa et al. reported only minor variations of BDNF baseline levels between responders and non-responders in a study of adjunctive treatment with lamotrigine in 46 TRD patients, while there was no prognostic correlation found between baseline levels of BDNF and responses to treatment, nor any important association between BDNF-level changes and the improvement of MADRS scores [17].
There have been few studies that managed to indicate a correlation between responses to treatment of TRD and other baseline growth factors. For example, Pisoni et al. found that among all growth factors studied, only vascular endothelial growth factor-C (VEGF-C) showed any prognostic correlation between the treatment response of a group of 36 patients and TRD. In this case, lower baseline levels before treatment were related to better responses to an add-on antidepressant treatment [32]. In another response study of add-on repeated transcranial magnetic stimulation (rTMS) in 15 patients with TRD by Fuduka et al., responders to the treatment showed higher initial concentrations of VEGF, while the percentage change in VEGF levels after treatment showed a statistically-significant correlation with the changes in psychometric scores of depressive symptomology [33]. Finally, in an i.v. 0.5 mg/kg ketamine infusion monotherapy study of 33 patients with TRD, Kiraly et al. showed that, among a large number of assessed biomarkers, only baseline serum levels of fibroblast growth factor 2 (FGF-2) were associated with treatment response, where low initial levels predicted better response to treatment [12].

2. Endocrine Biomarkers

MDD is considered a stress-related disorder with a unique pathophysiological neuroendocrine profile, presenting distinct changes in activity and reactivity of the HPA axis [34][35]. The most consistent findings include correlations between: the hyperactivity of the HPA axis and increased cortisol (CORT) levels, a higher corticotropin-releasing hormone (CRH) drive and higher adrenocorticotropic hormone (ACTH) and vasopressine (AVP) levels, and a weak cortisol awakening response (CAR) and the reduced sensitivity of glycocorticoid receptors [36]. It has also been shown that effective antidepressive treatment with reductions in depressive psychopathology is often related to a consequent normalization in the HPA-axis (re-)activity [36]. Apart from the baseline and diurnal levels of several HPA axis hormones (CRH, AVP, ACTH, CORT, and dehydroepiandrosterone—DHEA), neuroendocrine suppression or stimulation tests (e.g., dexamethasone, metyrapone) have often been used to study dynamic endocrine levels with respect to their possible prognostic significance in antidepressant response [36]. Nevertheless, the studies that investigated the baseline and diurnal activity, and dynamic responsiveness of the HPA axis in TRD, are proportionally scarce.
In one of the three available studies, Markopoulou et al. measured baseline CORT and DHEA and their ratio in 28 patients with TRD, noting their association with treatment responses to add-on pharmacological treatment [37]. In this research, while CORT levels were lower after the treatment, there was no correlation between baseline and post-treatment CORT levels and treatment outcome. On the contrary, the responders to treatment had significantly lower DHEA and showed a higher CORT/DHEA ratio both at admission and discharge compared to the non-responders, suggesting that, although remaining stable across treatment, the CORT/DHEA ratio could represent a prognostic biomarker of response to TRD. In another study, Dinan et al. examined therapeutic responses to add-on therapy using dexamethasone in 10 patients with SSRIs resistance and showed that higher baseline CORT levels predicted treatment response [38]. On the other hand, in a study of treatment responses to add-on sleep deprivation or sleep phase shift in 21 patients with TRD (unipolar and bipolar), Kurczewska et al. noticed that baseline CORT levels were significantly lower in responders than in non-responders [39].

3. Metabolic Biomarkers

3.1. Adipokines

Adipokines are cytokines, with hormonal action secreted by the lipid tissue (e.g., adiponectin, leptin, and resistin), are considered to participate in the pathophysiological pathways connecting obesity with cardiovascular diseases. In a 0.5 mg/kg i.v. ketamine infusion add-on study in 8 patients with unipolar/bipolar TRD, Machado-Vieria et al. showed that apart from the prognostic value of BMI, regarding the response to treatment with ketamine, lower baseline concentrations of adiponectin in the serum could predict antidepressant responses to ketamine [40].

3.2. Lipidemic Factors

Blood lipidemic factors have been implicated in MDD pathophysiology and especially in intra- and inter-neuronal functioning, and have been studied as biomarkers in MDD [41]. In TRD, only two studies have been found that assess blood lipidemic factors in relation to treatment response. In an add-on study with infliximab in 26 patients with TRD, Bekhbat et al. found that baseline levels of cholesterol, LDL, and non-HDL were higher in responders and also showed significant decreases (during treatment) in those patients with higher baseline CRP [42]. On the contrary, in a study of 92 TRD patients, Papakostas et al. reported that baseline levels of cholesterol > 200 mg/dL predicted a worse response to monotherapy with nortriptyline [43].

References

  1. Miller, A.H.; Raison, C.L. The role of inflammation in depression: From evolutionary imperative to modern treatment target. Nat. Rev. Immunol. 2016, 16, 22–34.
  2. Köhler-Forsberg, O.; NLydholm, C.; Hjorthøj, C.; Nordentoft, M.; Mors, O.; Benros, M.E. Efficacy of anti-inflammatory treatment on major depressive disorder or depressive symptoms: Meta-analysis of clinical trials. Acta Psychiatr. Scand. 2019, 139, 404–419.
  3. Beurel, E.; Toups, M.; Nemeroff, C.B. The Bidirectional Relationship of Depression and Inflammation: Double Trouble. Neuron 2020, 107, 234–256.
  4. Strawbridge, R.; Arnone, D.; Danese, A.; Papadopoulos, A.; Vives, A.H.; Cleare, A.J. Inflammation and clinical response to treatment in depression: A meta-analysis. Eur. Neuropsychopharmacol. 2015, 25, 1532–1543.
  5. Liu, J.J.; Bin Wei, Y.; Strawbridge, R.; Bao, Y.; Chang, S.; Shi, L.; Que, J.; Gadad, B.S.; Trivedi, M.H.; Kelsoe, J.R.; et al. Peripheral cytokine levels and response to antidepressant treatment in depression: A systematic review and meta-analysis. Mol. Psychiatry 2019, 25, 339–350.
  6. Chan, M.K.; Cooper, J.D.; Bot, M.; Birkenhager, T.K.; Bergink, V.; Drexhage, H.A.; Steiner, J.; Rothermundt, M.; Penninx, B.W.; Bahn, S. Blood-based immune-endocrine biomarkers of treatment response in depression. J. Psychiatr. Res. 2016, 83, 249–259.
  7. Gadad, B.S.; Jha, M.K.; Czysz, A.; Furman, J.L.; Mayes, T.L.; Emslie, M.P.; Trivedi, M.H. Peripheral biomarkers of major depression and antidepressant treatment response: Current knowledge and future outlooks. J. Affect. Disord. 2018, 233, 3–14.
  8. Mora, C.; Zonca, V.; Riva, M.A.; Cattaneo, A. Blood biomarkers and treatment response in major depression. Expert Rev. Mol. Diagn. 2018, 18, 513–529.
  9. Busch, Y.; Menke, A. Blood-based biomarkers predicting response to antidepressants. J. Neural. Transm. 2019, 126, 47–63.
  10. Strawbridge, R.; Young, A.H.; Cleare, A.J. Biomarkers for depression: Recent insights, current challenges and future prospects. Neuropsychiatr. Dis. Treat. 2017, 13, 1245–1262.
  11. Yang, J.J.; Wang, N.; Yang, C.; Shi, J.Y.; Yu, H.Y.; Hashimoto, K. Serum interleukin-6 is a predictive biomarker for ketamine’s antidepressant effect in treatment-resistant patients with major depression. Biol. Psychiatry 2015, 77, e19–e20.
  12. Kiraly, D.D.; Horn, S.R.; Van Dam, N.T.; Costi, S.; Schwartz, J.; Kim-Schulze, S.; Patel, M.; Hodes, G.E.; Russo, S.J.; Merad, M.; et al. Altered peripheral immune profiles in treatment-resistant depression: Response to ketamine and prediction of treatment outcome. Transl. Psychiatry 2017, 7, e1065.
  13. Kruse, J.L.; Congdon, E.; Olmstead, R.; Njau, S.; Breen, E.C.; Narr, K.L.; Espinoza, R.; Irwin, M.R. Inflammation and Improvement of Depression Following Electroconvulsive Therapy in Treatment-Resistant Depression. J. Clin. Psychiatry 2018, 79, 9042.
  14. Yang, C.; Wardenaar, K.J.; Bosker, F.J.; Li, J.; Schoevers, R.A. Inflammatory markers and treatment outcome in treatment resistant depression: A systematic review. J. Affect. Disord. 2019, 257, 640–649.
  15. Chen, M.H.; Li, C.T.; Lin, W.C.; Hong, C.J.; Tu, P.C.; Bai, Y.M.; Cheng, C.M.; Su, T.P. Rapid inflammation modulation and antidepressant efficacy of a low-dose ketamine infusion in treatment-resistant depression: A randomized, double-blind control study. Psychiatry Res. 2018, 269, 207–211.
  16. Strawbridge, R.; Jamieson, A.; Hodsoll, J.; Ferrier, I.N.; McAllister-Williams, R.H.; Powell, T.R.; Young, A.H.; Cleare, A.J.; Watson, S. The Role of Inflammatory Proteins in Anti-Glucocorticoid Therapy for Treatment-Resistant Depression. J. Clin. Med. 2021, 10, 784.
  17. Kagawa, S.; Mihara, K.; Suzuki, T.; Nagai, G.; Nakamura, A.; Nemoto, K.; Kondo, T. Both Serum Brain-Derived Neurotrophic Factor and Interleukin-6 Levels Are Not Associated with Therapeutic Response to Lamotrigine Augmentation Therapy in Treatment-Resistant Depressive Disorder. Neuropsychobiology 2017, 75, 145–150.
  18. Allen, A.P.; Naughton, M.; Dowling, J.; Walsh, A.; O’Shea, R.; Shorten, G.; Scott, L.; McLoughlin, D.M.; Cryan, J.F.; Clarke, G.; et al. Kynurenine pathway metabolism and the neurobiology of treatment-resistant depression: Comparison of multiple ketamine infusions and electroconvulsive therapy. J. Psychiatr. Res. 2018, 100, 24–32.
  19. Yoshimura, R.; Hori, H.; Ikenouchi-Sugita, A.; Umene-Nakano, W.; Ueda, B.; Nakamura, J. Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2009, 33, 722–726.
  20. Raison, C.L.; Rutherford, R.E.; Woolwine, B.J.; Shuo, C.; Schettler, P.; Drake, D.F.; Haroon, E.; Miller, A.H. A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: The role of baseline inflammatory biomarkers. JAMA Psychiatry 2013, 70, 31–41.
  21. Papakostas, G.I.; Shelton, R.C.; Zajecka, J.M.; Bottiglieri, T.; Roffman, J.; Cassiello, C.; Stahl, S.M.; Fava, M. Effect of adjunctive L-methylfolate 15 mg among inadequate responders to SSRIs in depressed patients who were stratified by biomarker levels and genotype: Results from a randomized clinical trial. J. Clin. Psychiatry 2014, 75, 855–863.
  22. Ochi, T.; Vyalova, N.M.; Losenkov, I.S.; Levchuk, L.A.; Osmanova, D.Z.; Mikhalitskaya, E.V.; Loonen, A.J.; Bosker, F.J.; Simutkin, G.G.; Bokhan, N.A.; et al. Investigating the potential role of BDNF and PRL genotypes on antidepressant response in depression patients: A prospective inception cohort study in treatment-free patients. J. Affect. Disord. 2019, 259, 432–439.
  23. Li, S.; Luo, X.; Hua, D.; Wang, Y.; Zhan, G.; Huang, N.; Jiang, R.; Yang, L.; Zhu, B.; Yuan, X.; et al. Ketamine Alleviates Postoperative Depression-Like Symptoms in Susceptible Mice: The Role of BDNF-TrkB Signaling. Front. Pharmacol. 2019, 10, 1702.
  24. Jin, Y.; Sun, L.H.; Yang, W.; Cui, R.J.; Xu, S.B. The Role of BDNF in the Neuroimmune Axis Regulation of Mood Disorders. Front. Neurol. 2019, 10, 515.
  25. Zhang, J.C.; Yao, W.; Hashimoto, K. Brain-derived Neurotrophic Factor (BDNF)-TrkB Signaling in Inflammation-related Depression and Potential Therapeutic Targets. Curr. Neuropharmacol. 2016, 14, 721–731.
  26. Piccinni, A.; Del Debbio, A.; Medda, P.; Bianchi, C.; Roncaglia, I.; Veltri, A.; Zanello, S.; Massimetti, E.; Origlia, N.; Domenici, L.; et al. Plasma Brain-Derived Neurotrophic Factor in treatment-resistant depressed patients receiving electroconvulsive therapy. Eur. Neuropsychopharmacol. 2009, 19, 349–355.
  27. Haile, C.; Murrough, J.W.; Iosifescu, D.V.; Chang, L.C.; Al Jurdi, R.K.; Foulkes, A.; Iqbal, S.; Mahoney, J.; De La Garza, R.; Charney, D.S.; et al. Plasma brain derived neurotrophic factor (BDNF) and response to ketamine in treatment-resistant depression. Int. J. Neuropsychopharmacol. 2013, 17, 331–336.
  28. Wilkinson, S.T.; Kiselycznyk, C.; Banasr, M.; Webler, R.D.; Haile, C.; Mathew, S.J. Serum and plasma brain-derived neurotrophic factor and response in a randomized controlled trial of riluzole for treatment resistant depression. J. Affect. Disord. 2018, 241, 514–518.
  29. Maffioletti, E.; Gennarelli, M.; Gainelli, G.; Bocchio-Chiavetto, L.; Bortolomasi, M.; Minelli, A. BDNF Genotype and Baseline Serum Levels in Relation to Electroconvulsive Therapy Effectiveness in Treatment-Resistant Depressed Patients. J. ECT 2019, 35, 189–194.
  30. Huang, X.B.; Huang, X.; He, H.B.; Mei, F.; Sun, B.; Zhou, S.M.; Yan, S.; Zheng, W.; Ning, Y. BDNF and the Antidepressant Effects of Ketamine and Propofol in Electroconvulsive Therapy: A Preliminary Study. Neuropsychiatr. Dis. Treat. 2020, 16, 901–908.
  31. Allen, A.P.; Naughton, M.; Dowling, J.; Walsh, A.; Ismail, F.; Shorten, G.; Scott, L.; McLoughlin, D.M.; Cryan, J.F.; Clarke, G.; et al. Serum BDNF as a peripheral biomarker of treatment-resistant depression and the rapid antidepressant response: A comparison of ketamine and ECT. J. Affect. Disord. 2015, 186, 306–311.
  32. Pisoni, A.; Strawbridge, R.; Hodsoll, J.; Powell, T.R.; Breen, G.; Hatch, S.; Hotopf, M.; Young, A.H.; Cleare, A.J. Growth Factor Proteins and Treatment-Resistant Depression: A Place on the Path to Precision. Front. Psychiatry 2018, 9, 386.
  33. Fukuda, A.M.; Hindley, L.E.; Kang, J.W.D.; Tirrell, E.; Tyrka, A.R.; Ayala, A.; Carpenter, L.L. Peripheral vascular endothelial growth factor changes after transcranial magnetic stimulation in treatment-resistant depression. Neuroreport 2020, 31, 1121–1127.
  34. Belmaker, R.H.; Agam, G. Major depressive disorder. Nat. Rev. Dis. Primers 2016, 2, 16065.
  35. Pariante, C.M.; Lightman, S.L. The HPA axis in major depression: Classical theories and new developments. Trends Neurosci. 2008, 31, 464–468.
  36. Stetler, C.; Miller, G.E. Depression and hypothalamic-pituitary-adrenal activation: A quantitative summary of four decades of research. Psychosom. Med. 2011, 73, 114–126.
  37. Markopoulou, K.; Papadopoulos, A.; Juruena, M.F.; Poon, L.; Pariante, C.M.; Cleare, A.J. The ratio of cortisol/DHEA in treatment resistant depression. Psychoneuroendocrinology 2009, 34, 19–26.
  38. Dinan, T.G.; Lavelle, E.; Cooney, J.; Burnett, F.; Scott, L.; Dash, A.; Thakore, J.; Berti, C. Dexamethasone augmentation in treatment-resistant depression. Acta Psychiatr. Scand. 1997, 95, 58–61.
  39. Kurczewska, E.; Ferensztajn-Rochowiak, E.; Jasinska-Mikolajczyk, A.; Chlopocka-Wozniak, M.; Rybakowski, J.K. Augmentation of Pharmacotherapy by Sleep Deprivation with Sleep Phase Advance in Treatment-Resistant Depression. Pharmacopsychiatry 2019, 52, 186–192.
  40. Machado-Vieira, R.; Gold, P.W.; A Luckenbaugh, D.; Ballard, E.; Richards, E.M.; Henter, I.; De Sousa, R.T.; Niciu, M.; Yuan, P.; A Zarate, C. The role of adipokines in the rapid antidepressant effects of ketamine. Mol. Psychiatry 2016, 22, 127–133.
  41. Parekh, A.; Smeeth, D.; Milner, Y.; Thuret, S. The Role of Lipid Biomarkers in Major Depression. Healthcare 2017, 5, 5.
  42. Bekhbat, M.; Chu, K.; Le, N.A.; Woolwine, B.J.; Haroon, E.; Miller, A.H.; Felger, J.C. Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression. Psychoneuroendocrinology 2018, 98, 222–229.
  43. Papakostas, G.I.; Petersen, T.; Sonawalla, S.B.; Merens, W.; Iosifescu, D.V.; Alpert, J.E.; Fava, M.; Nierenberg, A.A. Serum Cholesterol in Treatment-Resistant Depression. Neuropsychobiology 2003, 47, 146–151.
More
Information
Subjects: Neurosciences
Contributors MDPI registered users' name will be linked to their SciProfiles pages. To register with us, please refer to https://encyclopedia.pub/register : , , , , ,
View Times: 337
Revisions: 2 times (View History)
Update Date: 28 Jul 2022
1000/1000